ATE346150T1 - Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen - Google Patents

Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Info

Publication number
ATE346150T1
ATE346150T1 AT99922714T AT99922714T ATE346150T1 AT E346150 T1 ATE346150 T1 AT E346150T1 AT 99922714 T AT99922714 T AT 99922714T AT 99922714 T AT99922714 T AT 99922714T AT E346150 T1 ATE346150 T1 AT E346150T1
Authority
AT
Austria
Prior art keywords
relates
sh3d1a
disorders
gene
leukemia
Prior art date
Application number
AT99922714T
Other languages
English (en)
Inventor
Julie R Korenberg
Xiao-Ning Chen
Original Assignee
Cedar Sinai Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedar Sinai Health System filed Critical Cedar Sinai Health System
Application granted granted Critical
Publication of ATE346150T1 publication Critical patent/ATE346150T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT99922714T 1998-04-16 1999-04-16 Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen ATE346150T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8200798P 1998-04-16 1998-04-16

Publications (1)

Publication Number Publication Date
ATE346150T1 true ATE346150T1 (de) 2006-12-15

Family

ID=22168041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922714T ATE346150T1 (de) 1998-04-16 1999-04-16 Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Country Status (5)

Country Link
EP (1) EP1071774B1 (de)
JP (1) JP2002511267A (de)
AT (1) ATE346150T1 (de)
DE (1) DE69934107D1 (de)
WO (1) WO1999053062A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1922301A (en) * 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378809A (en) * 1992-08-25 1995-01-03 The United States Of America As Represented By The Department Of Health And Human Services Polynucleotides and substrate for the epidermal growth factor receptor kinase (eps8)
EP0833941B1 (de) * 1995-04-07 2008-10-22 Cytogen Corporation Polypeptide mit spezieller, funktioneller domäne, verfahren zu ihrer identifikation und anwendungen derselben
WO1999055728A2 (en) * 1998-04-27 1999-11-04 Hsc Research And Development Limited Partnership Ese genes and proteins

Also Published As

Publication number Publication date
EP1071774B1 (de) 2006-11-22
JP2002511267A (ja) 2002-04-16
WO1999053062A3 (en) 2000-04-20
EP1071774A2 (de) 2001-01-31
DE69934107D1 (de) 2007-01-04
WO1999053062A2 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
NO982785L (no) Kromosom 13-koblet brystkreftmottagelighetsgen
WO1996005307A3 (en) 17q-linked breast and ovarian cancer susceptibility gene
Bachelez et al. DEtection of clonal t-cell receptor? gene rearrangements with the use of the polymerase chain reaction in cutaneous lesions of mycosis fungoides and sézary syndrome
WO1996005306A3 (en) In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
Marcou et al. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity
Hanson et al. Germline CBL mutation associated with a noonan‐like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23
Srinivas et al. Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature
ATE122727T1 (de) Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten.
ATE346150T1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen
Mohammadi et al. Evaluation of mRNA Expressions of TOX and NR4As in CD8+ T cells in Acute Leukemia
WO1998025125A3 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
Ali et al. Adult‐onset acute myeloid leukaemia in a patient with germline mutation of CBL.
Irizarry et al. Leveraging naked mole rat (Heterocephalus glaber) comparative genomics to identify canine genes modulating susceptibility to tumorigenesis and cancer phenotypes.
Davrinche et al. Human properdin factor B: Gene frequency study in an African Negroid population (Niger)
Primartati et al. The Role of Interleukin-7 in T Cell Acute Lymphoblastic Leukemia: A Systematic Literature Review
Taylor et al. TBIO-06. BDNF-TRKB SIGNALING REGULATES NEURON-GLIOMA SYNAPTOGENESIS AND PROMOTES TUMOR PROGRESSION
Dang et al. TBIO-07. SINGLE-CELL TRANSCRIPTOMIC PROFILE REVEALS MACROPHAGE HETEROGENEITY IN SONIC-HEDGEHOG MEDULLOBLASTOMA AND THEIR DISTINCT RESPONSES TO DIFFERENT TREATMENT MODALITIES
Prince et al. TBIO-11. DEEP LEARNING-BASED SINGLE-CELL RNA SEQUENCING DIFFERENTIATION IDENTIFIES SIMPLE AND COMPLEX TRANSCRIPTIONAL NETWORKS FOR SUBPOPULATION CLASSIFICATION
Sangatsuda et al. TBIO-08. BASE-RESOLUTION METHYLOMES OF GLIOMAS BEARING HISTONE H3. 3 MUTATIONS REVEAL A G34 MUTANT-SPECIFIC SIGNATURE SHARED WITH BONE TUMORS
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
Ren et al. Curative effect of TCM-WM therapy on Wilson disease with different clinical phenotypes and polymorphisms of ATP7B gene
Wozna et al. The immunological, biochemical and molecular bases of canine senescence and carcinogenesis: a review.
AU3925701A (en) Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
MX9701076A (es) Metodo para diagnosticar una predisposicion para cancer de pecho y ovario.
de Leval et al. The Gene Expression Profile of Nodal T-Cell Lymphomas Identifies a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T Cells (TFH), and between CD30+ Peripheral T-Cell Lymphoma and ALK-Negative Anaplastic Large Cell Lymphoma (ALCL).

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties